Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9612 posts found.

novartis_outside_1

EU approval for Novartis’ Cosentyx in active non-radiographic axial spondyloarthritis

April 29, 2020 Research and Development, Sales and Marketing Cosentyx, EU, Novartis, axial spondyloarthritis, pharma

Novartis has revealed that the European Commission has moved to approve Cosentyx (secukinumab) for the treatment of active non-radiographic axial …
News
pharmafocus_may_2020_cover

The May 2020 issue of Pharmafocus is available to read free online now!

April 28, 2020 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, coronavirus, pharma

The latest monthly edition of Pharmafocus, the May 2020 issue, is available to read for free online now!
News
janssen_latest_logo_on_sign_closer

NICE backtracks to approve Janssen’s Stelara in ulcerative colitis

April 28, 2020 Manufacturing and Production, Research and Development Janssen, NICE, Stelara, ulcerative colitis

NICE has recommended Janssen’s Stelara (ustekinumab) for the treatment of moderately to severely active ulcerative colitis (UC), a move which …
News

Reinventing the value equation

April 27, 2020 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Drug pricing, feature, real world data, real world evidence, real-world data, real-world evidence

There is a duty to ensure access to innovative treatments for patients with unmet need, but a health service gatekeeper …
Feature
gilead-sciences

Leading COVID-19 hope remdesivir fails to provide clinical benefit in first randomised trial

April 24, 2020 Medical Communications, Research and Development COVID-19, Gilead, coronavirus, pharma, remdesivir

Gilead’s remdesivir, which has been hailed as one of the few truly promising treatments for COVID-19 at this early stage …
News

Novartis’ Jakavi Phase 3 trial is first of its kind to hit main goal in steroid-refractory acute graft-versus-host disease

April 23, 2020 Research and Development Jakavi, Novartis, pharrma

Novartis has revealed impactful new Phase 3 data for its therapy Jakavi (ruxolitinib) in the treatment of patients with steroid-refractory …
News
boehringer_biberach_germany_copy

Boehringer’s nintedanib approved in Europe for systemic sclerosis-associated interstitial lung disease

April 22, 2020 Research and Development, Sales and Marketing Boehringer Ingelheim, EU, nintedanib, pharma

The European Commission has moved to authorise Boehringer Ingelheim’s nintedanib in Europe for the treatment of systemic sclerosis-associated interstitial lung …
News
coroanrvisu_cdc

Pharmafile.com’s weekly COVID-19 news round-up

April 22, 2020 Research and Development COVID-19, coronavirus, hydroxychloroquine

Hydroxychloroquine has faced setbacks as a potential COVID-19 treatment, as it failed a clinical trial in France and a study …
News
testing_kit

First in-home COVID-19 testing kit approved by the FDA

April 22, 2020 Research and Development COVID-19, Testing kits, coronavirus, testing swabs

The US Food and Drug Administration have granted emergency clearance to the first in-home COVID-19 testing kit. The nasal swab …
News
abbvie_0

AbbVie’s Imbruvica scoops up 11th FDA approval with chronic lymphocytic leukaemia/small lymphocytic lymphoma nod

April 22, 2020 Research and Development, Sales and Marketing Cancer, FDA, imbruvica, leukaemia

AbbVie’s Imbruvica (ibrutinib) has scored its 11th FDA approval, this time in combination with rituximab for the treatment of chronic …
News
stock_drugs

National Institutes of Health says COVID-19 patients should not take hydroxychloroquine

April 22, 2020 Research and Development COVID-19, coronavirus, hydroxychloroquine

Experts at the US National Institutes of Health (NIH) have drafted treatment guidelines for the use of hydroxychloroquine in COVID-19 …
News
novartis_outside_1

Five-year data supports early treatment with Novartis’ Mayzent in secondary progressive multiple sclerosis

April 21, 2020 Manufacturing and Production, Research and Development Mayzent, Novartis, pharma

Novartis has pulled back the curtain on five-year data from an extension trial for its sphingosine 1-phosphate receptor modulator Mayzent …
News
ny

How the intended role of generic medicines is being undermined in America

April 20, 2020 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Drug pricing, US, feature, generic medicines, generics

The introduction of a generic medicine should, in theory, incentivise companies to lower the price of the original drug, creating healthy …
Feature
moderna-605x340

US Government’s BARDA to fund Moderna’s coronavirus vaccine by $483m

April 17, 2020 Medical Communications, Research and Development BARDA, COVID-19, Moderna, coronavirus, pharma

Moderna has secured $483 million in funding from the Biomedical Advanced Research and Development Authority (BARDA), to drive development and …
News
top_10_image_2

Top Ten most popular articles on Pharmafile.com this week

April 17, 2020 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, coronavirus, top 10

Hydroxychloroquine dominates the news as the potential COVID-19 treatment has gone through various trials. A Chinese study showed that the …
News
The Gateway to Local Adoption Series

Latest content

Kayentis and RWS partner to improve clinical trial data confidence

April 17, 2026

MHRA expands its pioneering AI Airlock programme with £3.6m funding boost

April 16, 2026

Ardena opens new US bioanalytical laboratory

April 15, 2026

Gesynta Pharma doses first patient in endometriosis phase 2 trial

April 14, 2026

Astellas Pharma’s new non-hormonal menopausal hot flush treatment Veoza can be used in the NHS, NICE says

April 13, 2026